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Abstract
Background: Depression is common among persons with epilepsy (PwE), affecting roughly one in three individuals,
and its presence is associated with personal suffering, impaired quality of life, and worse prognosis. Despite the availability
of effective treatments, depression is often overlooked and treated inadequately in PwE, in part because of assumed
concerns over drug interactions or proconvulsant effects of antidepressants. Internet-administered psychological
interventions might complement antidepressant medication or psychotherapy, and preliminary evidence suggests that
they can be effective. However, no trial has yet examined whether an Internet intervention designed to meet the needs
of PwE can achieve sustained reductions in depression and related symptoms, such as anxiety, when offered as adjunct
to treatment as usual.
Methods/Design: This randomized controlled trial will include 200 participants with epilepsy and a current depressive
disorder, along with currently at least moderately elevated depression (Patient Health Questionnaire (PHQ-9) sum score
of at least 10). Patients will be recruited via epilepsy treatment centers and other sources, including Internet forums,
newspaper articles, flyers, posters, and media articles or advertisements, in German-speaking countries. Main inclusion
criteria are: self-reported diagnosis of epilepsy and a depressive disorder, as assessed with a phone-administered structured
diagnostic interview, none or stable antidepressant medication, no current psychotherapy, no other major psychiatric
disorder, no acute suicidality. Participants will be randomly assigned to either (1) a care-as-usual/waitlist (CAU/WL) control
group, in which they receive CAU and are given access to the Internet intervention after 3 months (that is, a CAU/WL
control group), or (2) a treatment group that may also use CAU and in addition immediately receives six-month access
to the novel, Internet-administered intervention. The primary outcome measure is the PHQ-9, collected at three months
post-baseline; secondary measures include self-reported anxiety, work and social adjustment, epilepsy symptoms (including
seizure frequency and severity), medication adherence, potential negative treatment effects and health-related quality of life.
Measurements are collected online at pre-treatment (T0), three months (T1), six months (T2), and nine months (T3).
Discussion: Results of this trial are expected to extend the body of knowledge with regard to effective and efficient
treatment options for PwE who experience elevated depression and anxiety.
Trial registration: ClinicalTrials.gov: NCT02791724. Registered 01 June 2016.
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Background
Among persons with epilepsy (PwE), depression is exceed-
ingly common and is associated with intense personal
suffering and dramatic reductions in quality of life [1]. Ac-
cording to a recent systematic review, 23.1% of PwE are
affected by depression within the past year [2], compared
to 6.6% in the general population [3]. Lifetime depression
prevalence is estimated at 30 to 35 percent among PwE
[4], compared to 16.2% in the general population [3].
Even though their frequent co-occurrence has been
observed repeatedly, questions remain regarding the
causal mechanisms underlying the relationship between
epilepsy and depression. The conventional view has long
held that depression arises as a consequence of having
epilepsy, but evidence is not consistent with such unidir-
ectional causation [4–7]. Indeed, experiencing depres-
sion before seizure onset may increase risk for the
subsequent development of epilepsy and, vice versa,
having epilepsy may increase subsequent depression risk
[5]. Research suggests that multiple pathogenic mecha-
nisms might explain the common co-occurrence of
epilepsy with depression and related syndromes, such as
anxiety [4]. These include common neurobiological
pathways, including neurotransmitter disturbances, brain-
structural or neuropathological abnormalities, and psycho-
social pathways, such as inadequate social support, stigma
or maladaptive coping [1, 4, 6, 8]. Additionally, iatrogenic
pathways must also be considered, as some antiepileptic
drugs facilitate depression and anxiety symptoms [6].
Research has attempted to identify sociodemographic
and disease-related risk factors for depression and
anxiety among PwE, albeit with limited success [9].
According to a recent systematic review, age and gender
are not associated consistently with depression, whereas
seizure frequency and recency appear to increase depres-
sion risk [9]. Different seizure types, however, are not
linked differentially with depression or anxiety. Overall, it
remains difficult to predict the course of psychiatric symp-
toms among PwE from known patient characteristics,
even though an increased general risk has been estab-
lished, compared to healthy comparison populations.
Several pharmacological and psychosocial depression
and anxiety treatments have been shown to be effective
among PwE. A recent systematic review reported that
cognitive behavioral therapy (CBT) might help alleviate
depression among PwE, although it appears to be less
effective for seizure control, and more high-quality
studies are needed before definitive conclusions can be
drawn [10]. Even though CBT and perhaps other forms
of psychotherapy are promising treatments for anxiety
or depression among PwE, they require the availability
of trained therapists, ideally with experience in treating
PwE, which is often unrealistic in many treatment set-
tings. According to an international expert consensus
statement, CBT as well as psychotropic medication
(particularly selective serotonin reuptake inhibitors) are
recommended for the treatment of depression and anxiety
in PwE [11]. Unfortunately, though, the vast majority of
depressed PwE typically do not receive any depression-
related treatment; in a recent study, depression remained
untreated in 70% of depressed PwE [12].
Even though treatments with some degree of effective-
ness exist, then, depression and anxiety often remain
undetected and undertreated among PwE, for at least
two reasons: (1) Epilepsy symptoms can overlap with or
mask psychiatric symptomatology, making detection
difficult and ambiguous (e.g., fatigue can be a symptom
of epilepsy, depression, or both), and (2) physicians are
often reluctant to prescribe antidepressants because of
concerns over side effects, drug interactions, or lowered
seizure thresholds [13]. Additionally, other barriers may
prevent depressed individuals from seeking or accessing
depression treatment, including stigma concerns, time
constraints, lack of motivation, skepticism regarding
psychotherapy, disease-related restrictions (e.g., inability
to drive), and perceived lack of necessity [14]. It is
important, though, to identify depression, overcome
potential barriers, and initiate treatment, as untreated
depression in PwE may increase risk for work absentee-
ism, increased health care system utilization, and direct
medical costs [15].
To improve access and extend the range of available
depression treatment options, Internet-based treatments
could play a key role [16, 17]. Indeed, several Internet-
based interventions have been developed and tested over
the past decade and are making a considerable impact
upon the field of mental health care delivery [18, 19]. As
early as 2002, expert panels have recommended exploit-
ing the Internet to deliver evidence-based psychological
treatments to underserved populations [20], and recent
systematic reviews and meta-analyses have confirmed
that some such interventions, most of which are based
on CBT-principles, are effective for a range of psychi-
atric symptoms and conditions, including depression
and anxiety disorders [21–23]. However, this body of
research has also been criticized: many trials are con-
ducted solely online, without establishing contact with
participants to verify identity and diagnoses, and they
suffer from various methodological problems such as
excessive attrition and lack of follow-up data [24].
Nevertheless, at least in some countries, including
Sweden, the Netherlands, Australia, and the United
Kingdom, Internet-based psychological interventions
with robust evidence are finding their ways into national
treatment guidelines and are increasingly integrated in
routine care services for patients suffering from depres-
sion, anxiety, and other psychiatric conditions [18, 25, 26].
Despite the considerable promise and success of some
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Internet-based psychological interventions, though, they
have rarely been applied to the treatment of depression
and anxiety among PwE.
To our knowledge, only one randomized controlled
trial to date has examined whether an Internet-
administered intervention can reduce depression among
PwE [27]. In this study, Schröder et al. randomized 78
PwE either to a care-as-usual (CAU) control or to an
intervention condition, in which participants received
CAU plus access to a depression-focused Internet inter-
vention termed Deprexis, which has been tested in non-
epilepsy samples in seven additional studies [28–34]. In
the Schröder et al. trial, participants in the intervention
group experienced significantly greater depression
reduction than those in the control group over the
course of nine weeks, with a small to moderate post-
treatment between-groups effect size (Cohen’s d = .43).
The study suffered from some methodological limita-
tions, though, including lack of long-term follow-up data
and structured diagnostic interviews. Perhaps most
importantly, the intervention was not tailored to address
the unique needs of PwE, as noted by the authors: “In
their subjective appraisal … most participants found that
the program should be adapted to the special needs of
PwEs with respect to involving more epilepsy-related
topics, [which] … could increase the acceptability as well
as the effectiveness of the intervention in this particular
patient group” [27]. The Deprexis program also does not
target anxiety, which is a common comorbid condition
among PwE and correlates as highly as r = .75 with
depression [1, 6, 35], justifying the development of inter-
ventions for both syndromes rather than just one.
The goal of the present randomized controlled trial
(RCT) is to test the efficacy of a novel CBT-based,
depression-focused Internet intervention that specifically
addresses the needs of PwE. This new program was devel-
oped by the same group of therapists and researchers that
developed Deprexis, the above-mentioned intervention
that was shown to be effective in the treatment of depres-
sion among PwE. The novel intervention has been devel-
oped and is operated by Gaia, an e-Health company with
more than ten years of experience in the development of
e-Health interventions, located in Hamburg, Germany.
The content and technical design of this intervention are
described in the methods section below.
The goal of this parallel-groups, pragmatic RCT is to
evaluate the extent to which a novel Internet interven-
tion, used adjunctively to CAU, can contribute to
improving symptoms of depression and anxiety, social-
occupational functioning, physical health (epilepsy
symptoms), medication adherence, and health-related
quality of life, among PwE. Furthermore, the trial aims
to evaluate the extent to which patients with epilepsy
regard this intervention as a helpful and valuable tool.
The primary focus of the software-based intervention is
on facilitating depression reduction; hence, this is the
target identified in the primary hypothesis.
It is hypothesized that, between baseline and three
months, patients randomized to the intervention group
will report greater reductions in depression, as measured
by the Patient Health Questionnaire (PHQ-9), a well
validated depression measure [36, 37], compared to
patients randomized to the control condition. The goal
of this pragmatic RCT [38] is to test the effectiveness of
a novel Internet intervention on depression reduction
among PwE over a period of three months, in compari-
son to a CAU/waitlist (CAU/WL) control group, which
only receives access to the intervention after three
months. Data will also be collected at six and nine
months, which will allow us to examine the stability of
intervention effects over time.
Secondary measures are administered to examine effects
of the intervention on anxiety symptoms, stress symp-
toms, and depression-related psychosocial impairment,
and it is hypothesized that participants assigned to the
intervention group will show greater improvements in
these respective measures over three months, compared
to control group participants. Exploratory analyses will be
conducted to examine potential negative effects of the
intervention, effects on epilepsy symptom severity and
seizure frequency, health-related quality of life, epilepsy
self-management, and medication adherence. The
subjective usefulness of the intervention will also be exam-
ined, and we expect that users will rate the intervention
favorably, given that it was developed to address several of
their epilepsy-specific needs and concerns.
Methods/Design
Study design
The content of this RCT as well as the design is in
accordance to the guidelines for clinical trial protocols
as specified the by the SPIRIT 2013 statement [39].
Moreover, this RCT is registered in ClinicalTrials.gov
(NCT02791724). Any changes to this trial protocol will
be described in this trial registry. Patients will be
randomized to two groups: (1) a control group, in which
they may engage with any epilepsy treatment and receive
access to the Internet intervention after a delay of three
months (CAU/WL), or (2) to a treatment group that im-
mediately receives six-month access to the Internet
intervention and may also use CAU (see Fig. 1 for flow
chart). Patients will be recruited consecutively from vari-
ous sources, including epilepsy treatment centers and
outpatient clinics, with every patient having an equal
chance of being assigned to the intervention or control
group (no block randomization). Randomization will be
performed by the Principal Investigator (PI), using a
computer-generated sequence to generate the allocation
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sequence. Participants will be enrolled by trained research
associates; the allocation sequence will be concealed from
them. Given the pragmatic design, participants are not
blinded as to group assignment.
Consistent with the logic governing pragmatic RCTs,
the trial will examine whether utilizing this program will
improve depression outcome above and beyond the
routine care patients are actually receiving [38, 40, 41].
Furthermore, particular attention will be paid to poten-
tial negative effects of the program, as assessed by a
questionnaire. The trial thus aims to maximize external
validity by contrasting the realities of current clinical
care with the addition of an Internet intervention; it
does not aim to maximize internal validity by selecting a
maximally homogeneous patient group or introducing
many other artificial control measures, such as narrow
inclusion and exclusion criteria that do not reflect the
clinical reality outside of trials [40].
Recruitment and assessment
Participants will be recruited from various settings, in-
cluding epilepsy treatment clinics, outpatient treatment
centers, epilepsy support groups, Internet forums and
groups, or Facebook pages. Methods such as newspaper
articles, flyers, posters, and media articles or web-
advertisements will be used to inform potential partici-
pants about the study (all material will be in German).
Treatment centers are informed about the goals and
procedures of the study; they were provided with
information material (study flyers, posters or leaflets)
that can be distributed to patients. This information
material was scrutinized by the locally responsible ethics
board prior to study commencement. Patients who are
interested in participating are invited (in the printed
study material) to sign up with their name and e-mail
address at an online study website (https://de.research.-
net/r/epilepsie-studie). A member of the research team
will then contact the potential participant by e-mail
within one week in order to invite the person to the
online baseline assessment (T0). Part of this online base-
line assessment is to provide further information about
the study as well as to provide informed consent to
participate (the informed consent form in German is
available on request from the first author). After com-
pleting the T0 online assessment and provided that
informed consent is given, the research team associate
will then conduct a telephone interview in order to
check inclusion/exclusion criteria and confirm the diag-
nosis of a depressive disorder with a structured diagnostic
interview (the MINI, as used in previous studies by this
group [32, 42, 43]). After the telephone interview, patients
will be randomized and will be asked to complete
3-months (T1, post-treatment), 6-months (T2), and 9-
months (T3) online assessments (see Table 1). The T1
(post-treatment) assessment will permit us to examine
whether treatment response can be documented after this
relatively brief period, as has been shown in previous trials
with a similar intervention [27–32]. The T1 assessment
Fig. 1 Flow diagram of the randomized controlled trial
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will be the time-point at which the intervention group but
not the control group has used the intervention, thus per-
mitting us to test the primary hypothesis that depression
reduction will differ over three months between the inter-
vention versus control groups.
Inclusion criteria
The inclusion criteria for this trial are as follows:
(1)Age at least 18 years,
(2)diagnosis of active epilepsy (that is, at least one
unprovoked epileptic seizure within the past
10 years or taking antiseizure medication within
the past five years in the context of epilepsy [44]),
(3)current depressive disorder (either major depressive
disorder or dysthymic disorder, as determined by
telephone interview with the MINI [43]),
(4)currently at least moderate self-reported depressive
symptom severity, as operationalized by a score of at
least 10 on the PHQ-9, a cut-off score that has been
well validated [45, 46],
(5)ability to speak and read German,
(6)access to the Internet and personal possession of
an appropriate device on which the Internet-based
intervention can be used regularly (e.g., modern
smartphone, computer, laptop),
(7)motivation to participate in the trial and use an
Internet-based intervention to acquire skills and
knowledge that may aid in the amelioration of de-
pression symptoms.
Exclusion criteria
Exclusion criteria are as follows:
(1)Newly prescribed antidepressant medication or
changes in antidepressant dosage during the one
month prior to study inclusion (medication changes
after study inclusion are permitted, given the
pragmatic design of the trial),
(2)currently in psychotherapy,
(3)presence of bipolar disorder, schizophrenia or
another psychotic disorder, or borderline
personality disorder (based on the MINI
interview),
(4)presence of acute suicidality (that is, no intention
or plan to commit suicide, as assessed with the
respective module of the MINI),
Intervention
The Internet-based intervention evaluated in this trial
was designed with the aim of conveying evidence-based
psychotherapeutic techniques, based on CBT, to PwE
over a period of 180 days. The intervention is fully self--
guided (i.e., no guidance or support from a clinician is
provided) and focuses on identifying and challenging
cognitions that trigger or sustain depression and anxiety,
increasing activities that are likely to reduce depression
and anxiety, practicing relaxation and stress manage-
ment exercises and increasing mindfulness skills (see
below for a more detailed content description). The
program is based on general CBT, evidence-based
psychotherapeutic techniques that have been shown to
be helpful for patients suffering from depression (and
ideally, that have been shown to be helpful among PwE).
Furthermore, program content addresses other important
issues in disease self-management, including lifestyle
habits (e.g., nutrition, exercise) and medication adherence.
Table 1 Study measures and measurement points










T0 baseline X X X X X X X X X X
T1 (3 months
post-baseline)
X X X X X Xl Xl X X X X
T2 (6 months
post-baseline)
X X X X X X Xm X X X
T3 (9 months
post-baseline)
X X X X X Xm X X X
aMINI Neuropsychiatric Interview
bPatient Health Questionnaire
cNeurological Disorders Depression Inventory for Epilepsy
dGeneralized Anxiety Disorder questionnaire, 7 items
eDepression and Anxiety Scales
fWork and Social Adjustment Scale
gInventory for the Assessment of Negative Effects of Psychotherapy
hPESOS and Liverpool Seizure Severity Scale (LSSS)
iRief Adherence Index (RAI)
jQOLIE-10-P (Quality of Life Inventory in Epilepsy)
kEpilepsy Self-Management Scale
lOnly patients in the intervention group
mOnly patients in the control group
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The delivery and training of content is continuously indi-
vidualized to match users’ preferences and needs, based
on responses within the program. Epilepsy patients are
guided through the program by rule-based artificial
intelligence algorithms that use patient responses as input.
The intervention is delivered via the Internet and pro-
tected by individually assigned passwords.
In the development process, several steps were taken
to ensure the quality and safety of the software: (1) The
program was developed by an experienced team consist-
ing of clinical psychologists, CBT therapists, physicians,
software engineers, graphic artists, speakers, and sound
engineers, among others. This team has already devel-
oped several other programs with demonstrated safety
and efficacy in clinical trials [28, 32, 47–51], (2) volun-
teers (PwE) were involved continuously throughout the
development process to test preliminary versions and
provide feedback, consistent with development guide-
lines [52, 53], (3) expert feedback was sought from
several physicians specializing in the treatment of
epilepsy, who reviewed the program, participated in in-
formal discussion rounds with the developers, and pro-
vided written feedback. Additionally, literature on
previous CBT developments among PwE was reviewed
[10, 54–56]. The development of the program took place
over a period of approximately one year in 2015.
The intervention was designed to be fully functional
on current generation smartphones (e.g., iPhone 6 and
7) as well as on technologically simpler, older, low-cost
smartphones that have Internet connectivity. Moreover,
the intervention can be used on smartphones as well as
larger-screen devices (tablet-PCs, laptops, desktop PCs),
with seamless integration and continuity for individual
users (e.g., users can freely switch back and forth among
different devices, always continuing where they left off,
or find features that accumulate over time on any given
device, provided that they log on with their unique user-
ID). Like other Internet interventions developed by this
group, the software-based intervention uses cloud
computing with fast global access and is securely hosted
in an ISO-27001-certified data center located in Germany.
The systems use a CE-certified platform technology, and
other programs developed by this group, such as Deprexis
[28, 32, 49], are certified as medical devices across the
European Union.
Like other programs developed by this group, the
intervention described herein is produced on a propri-
etary software (broca®) that was developed by Gaia in
the early 2000s and is currently in its fourth iteration.
This software is designed to allow for extensive tailoring
of content to match both stable and dynamically
changing user requirements, consistent with evidence
showing the superiority of tailored over generic health
behavior interventions [57]. The programs engage users
in simulated “dialogues” of varying length in which brief
content chunks are continuously followed by response
options. Depending on which responses are selected,
subsequent content is altered to match emerging prefer-
ences or requirements - analogous to the type of
“responsiveness” that effective psychotherapists use to
change micro-interventions throughout the course of
treatment [58]. Tailoring may enhance the personal
relevance of information and lead to enhanced cogni-
tive activity and information retrieval, which may
explain, to an extent, the superior effects of tailored
interventions [59].
An outline of main content and program features is
provided below. Each of five modules contains content
that can be explored in briefer or longer individual
sessions, depending on personal preferences. Depending
on factors such as reading speed, interest to explore con-
tent in greater or lesser depth, and desire to listen to a
greater or smaller number of audio recordings, each
module can be completed in approximately 60 to
180 min. Thus, it would be possible to work through the
entire program in as little as approximately five hours,
or one could choose to spend much more time with it.
As in other programs developed by our group [27–34, 48],
there is no fixed or generic sequence in which modules
must be completed, nor a minimum number of sessions
that must be finished. Users are invited to freely explore
the program and let themselves be guided within each
section by the algorithm-driven sequences generated by
the program. They are also informed that they can discon-
tinue the program at any time if they feel that the program
is not helpful or even harmful, and they are invited to
contact the Principal Investigator, a licensed clinical
psychologist, if they seek further help or advice. The
purpose of such contacts would be only to provide infor-
mation regarding treatment options, if clinically required,
but not to provide therapeutic support. To define minim-
ally sufficient usage, we are using the same algorithm we
have used previously [32]: Having started at least four
sessions and spent a total of least 60 min actively engaged
with the program.
Program elements:
(1)Introductory module: The introductory module
provides an overview of the purpose, functions, and
time-frame of the program. Patients are engaged in
interactive sequences in which the CBT approach
is briefly explained and in which their current and
past medical and psychiatric history are explored.
The introductory module addresses topics such as
epilepsy onset and severity, types and intensity of
current depression and anxiety symptoms, as well
as exercise and nutrition habits. Patients are provided
with a summary (“personal profile”) of their responses,
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and recommendations are made for further topics that
patients may wish to engage with in subsequent
sessions. The recommendation is made that patients
use the program several times per week, as they see
fit, for at least three months. They are informed that
program access is provided for a six-month period.
(2)Depression module: The depression module is
individualized in such a manner that patients can
continuously explore topics in greater or lesser depth
and are presented with content that is adapted to
their previously expressed concerns and needs. The
module is structured, on a broad level, in two separate
sections: (a) a psychoeducational part in which topics
such as depression symptoms and treatment options
can be explored interactively, and (b) an intervention
part in which CBT-based techniques, such as
identifying negative automatic thoughts and cognitive
distortions as well as challenging or refuting unhelpful
thoughts (cognitive modification), can be learned and
practiced. In the latter part, patients learn about the
nature and functions of negative automatic thoughts
and cognitive distortions, they are presented with a
rationale for activity scheduling and the principles of
behavioral activation, they are offered several
mindfulness and acceptance exercises, and they
have the option of engaging with cognitive bias
modification for interpretation techniques [60–62].
As in all other parts of the program, references and
suggestions for further information are provided.
(3)Anxiety module: The anxiety module is broadly
consistent with contemporary CBT and transdiagnostic
approaches to anxiety [63–65], which have already
been shown by our group to be effective when
delivered via an Internet intervention [48]. Interactive
sequences are used to explain the nature and function
of anxiety, emphasizing the idea that anxiety can serve
a useful function (e.g., signaling potential danger) but
can be unhelpful when it is automatically triggered
easily in the absence of actual danger (i.e., “false alarm”
model). Core CBT principles are explained, such as
exposure, avoidance behavior, cognitive restructuring,
acceptance of aversive emotions, willingness to pursue
valued goals even in the presence of anxiety, and
mindfulness and relaxation exercises. Content is
focused on concerns relevant for PwE, such as
experiencing future seizures or worsening symptoms,
not being able to drive, not functioning on the job,
experiencing side effects, social embarrassment, or
becoming a burden for others [66, 67]).
(4)Coping with epilepsy symptoms module: This module
focuses on several epilepsy-specific topics, including
(a) medication adherence (e.g., exploring motivation
with regard to medication-taking, using decisional
balance exercises in which perceived advantages
and disadvantages of taking medications are weighed,
fostering self-efficacy [68]), (b) identifying and coping
with seizure auras and triggers [55, 69, 70], (c) dealing
with stigma and discrimination [71], (d) reflecting on
values and life goals that are realistic and attainable
even with a condition such as epilepsy [72, 73].
(5)Lifestyle modification module: This module focuses
on topics such as the role of exercise and dieting/
nutrition in the management of epilepsy. There is
persuasive evidence that both exercise and healthy
nutrition affect depression and anxiety, both in healthy
populations and among those with chronic illnesses
[74–78]. Epilepsy-specific topics are explored
interactively in some depth, such as the potential utility
of adopting a ketogenic diet [79] and the advantages
and risks of different types of exercise [80].
(6)Symptom tracking: Self-monitoring of symptoms is an
essential aspect of CBT that is particularly suitable for
mobile interventions [81] and has been integrated
successfully in previous Internet interventions
developed by our group [48, 49]. In this intervention,
items from a validated questionnaire [82] that assesses
the severity of depression and anxiety symptoms are
integrated. Patients are invited to complete the items
at regular intervals and track their symptom severity
via visual and text-feedback that is provided in
the program.
Similar to other Internet interventions developed by
our group, this intervention also includes the follow-
ing elements: (a) optional daily text messages (either
via SMS or e-mail) for 90 days, in which brief motiv-
ational content is conveyed, (b) worksheets and brief
summaries of module content, (c) audio recordings
within each module. Program usage is tracked auto-
matically by the software.
Outcome measurements
All outcome measurements will be collected via a se-
cure, encrypted online survey service. Participants will
be invited via e-mail to complete the online self-report
measures, and up to two reminder e-mails will be sent if
they do not respond to the initial invitation.
Primary outcome
The primary outcome, symptoms of depression, will
be measured at T0, T1, T2, and T3 by the PHQ-9, a
well-validated measure of depressive symptom sever-
ity [36, 37]).
Secondary outcomes
The following instruments will be used to assess secondary
outcomes. Each instrument will be administered at T0, T1,
T2, and T3, except of the Inventory for the Assessment of
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Negative Effects of Psychotherapy (INEP), the items regard-
ing the subjective usefulness of the program and the Epi-
lepsy Self-Management Scale (ESMS).
1. The NDDIE (Neurological Disorders Depression
Inventory for Epilepsy [83]) will be used as a
secondary measure of depression symptom severity.
2. GAD-7 (Generalized Anxiety Disorder questionnaire,
7 items) [84, 85]: The GAD-7 is a well-validated
measure of anxiety symptom severity. Originally
developed to assess symptoms of generalized anxiety
disorder, it has been shown to be a valid and reliable
measure of anxiety severity more broadly
conceptualized.
3. DASS-21 (Depression and Anxiety Scales) [82]: The
DASS-21 is a valid and reliable brief questionnaire
of depression, anxiety, and stress symptoms.
4. WSAS (Work and Social Adjustment Scale) [86]:
The WSAS is a validated brief index of psychosocial
impairment caused by depression (e.g., inability to
work or pursue hobbies due to depression). The
WSAS has been used in previous research by this
group; psychometric properties have been found to
be adequate [28].
5. Subjective usefulness of the program: measured by
individually designed items, as in previous studies
by this research group [28, 29, 32]. The items will
be administered after using the intervention
(intervention group: T1 and T2, control group:
T2 and T3).
6. INEP: INEP is a reliable self-report instrument for
assessing potential negative effects of psychothera-
peutic treatment. A version that has been adapted
to inquire about potential negative effects of
Internet interventions is used here [87]. The
INEP will be administered after 3-month using
the intervention (intervention group: T1, control
group: T2).
7. Epilepsy symptom severity: measured by validated
measures (e.g., seizure frequency and severity; PESOS
(Performance, Sociodemographic aspects, Subjective
evaluation) [88] and LSSS (Liverpool Seizure Severity
Scale) [89]).
8. Medication adherence: Measured by a brief, validated
questionnaire, such as the 4-item Rief Adherence
Index (RAI) [90].
9. Health-related quality of life: Measured with a
validated questionnaire that assesses quality of life
among PwE, the QOLIE-10 (Quality of Life Inventory
in Epilepsy) [91].
10.ESMS: The ESMS is a reliable questionnaire that
assesses frequency of use of epilepsy self-
management practices [92]. The ESMS will be
administered at T0 and T1.
Additionally, several items will be administered at the
relevant time-points to assess specific demographic
characteristics (e.g., age, gender) and illness-related
parameters including:
 Frequency of interfering seizures (at T0):
– “Did you experience at least one seizure within
the past year?” (yes, no)
– If no: “When did you last experience a seizure
that interfered with your ability to pursue your
normal activities?”
– “How often are you currently typically
experiencing seizures that interfere with your
ability to pursue your normal activities?” (no
seizures, 1–5 seizures per month, 6–10 seizures
per month, > 10 seizures per month)
 Seizure frequency at subsequent time-points (at
T1, T2, T3):
– “Did you experience at least one seizure within
the past three months?” (yes, no)
– If yes: “Over the past three months, how many
seizures have you experienced that interfered
with your ability to pursue your normal
activities?”
 Current medication (at all time-points):
– “Which seizure medicine(s) are you currently
taking? (please list)”
Sample size calculation and analysis
The sample size of this study is based on the expected
difference on the primary outcome variable (depressive
symptom severity), between the intervention group and
the control group at T1 (three months). Based on a
power of at least 0.80 in a two-tailed test and an alpha
of 0.05, randomization of 200 subjects (100 per group)
will be sufficient to show an effect-size of d = 0.50 (mod-
erate effect), anticipating an attrition rate of maximally
20% at T1, a rate that has been achieved in several previ-
ous trials [29–32]. With an anticipated sample size of
160 (2 × 80) completers at T1, power of .88 would be
achieved for a moderate effect size of d = 0.50. Based on
previous research by this group [27–29, 32], the assump-
tion of achieving a moderate effect appears realistic. This
power calculation is based on the assumption that an
even randomization procedure (50:50) will be used.
Analyses will conform to recommended methodological
standards, as specified by the CONSORT statement [93].
Specifically, both intention-to-treat and per-protocol ana-
lyses will be conducted, using appropriate methods such
as linear mixed-models, which are widely used in this field
and have been recommended because of their capacity to
handle missing data appropriately [94, 95]. It is anticipated
that attrition rate at post-treatment will be below 20%,
given previous trial experiences [29, 31, 32]. Additional
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analyses will be performed to examine the potential influ-
ence of confounding variables on changes in the primary
outcome (e.g., initial differences in symptom severity or
treatment utilization).
Conflict of interest, scientific integrity and independence
It is not unusual for intervention developers to be in-
volved in trials that examine their efficacy; indeed, this is
the rule rather than the exception and will also be the
case in this study. However, measures will be taken to
ensure that potential conflicts of interests do not
jeopardize the scientific integrity of data collection,
analysis, or any other aspect of the study. Firstly, the
Principal Investigator (YN) is an independent established
researcher in the field of clinical psychology and psycho-
therapy without financial or other ties to the developers,
operators, and sponsors of this project (i.e., YN does not
receive remuneration or other compensation from Gaia,
the developers). Secondly, the Principal Investigator and
members of her research team will have full and
continuous access to all data being collected in this
study (provided, of course, that informed consent to this
is granted by participants at study commencement).
Data monitoring will be performed by the Principal
Investigator, who is independent from the sponsor and
has no competing interests. All adverse events will be re-
ported; interim analyses are not planned. The day-to-day
management of the study (e.g., contacting participants
and inviting them to complete online surveys) will be
performed by research associates working at Gaia, the
intervention developer, which is an e-Health enterprise
with an established track record of multicenter research
[28, 32, 42, 96]. Publication of results will be sought
regardless of study outcome, i.e., even if the intervention
should prove to be ineffective. A summary of the results
will also be made available for trial participants after
completion of the trial.
Discussion
This protocol describes a methodological rigorous, statis-
tically adequately powered trial of a novel Internet-based
psychological treatment for depression and anxiety among
PwE. There is an urgent need for innovate and low-
threshold interventions in this area, given that depression
and anxiety are exceedingly common in epilepsy, compli-
cate treatment response and prognosis, dramatically
reduce quality of life, and yet often remain undetected and
are treated inadequately. The personal suffering and
societal burden associated with depression among PwE
could potentially be reduced by Internet-based interven-
tions such as the one evaluated in this trial.
Although the allegedly low costs of Internet-based
interventions are often emphasized, developing and
maintaining effective, technologically adequate and
secure Internet interventions incurs considerable ex-
penses. In this project, a research-focused e-Health com-
pany is driving the development of a novel Internet
intervention and investing considerable resources to
enable the conduct of a methodologically rigorous, inde-
pendent scientific investigation, whose results will be
published regardless of whether they are consistent with
the research hypothesis, and the hopes or expectations
of the program developers. Several collaborating investi-
gators with no conflicts of interest will ensure the scien-
tific integrity and independence of this project. In our
view, this type of collaborative arrangement seems ethic-
ally responsible and scientifically viable. Along with
others [19, 97, 98], we feel confident that evidence-based
Internet interventions will increasingly be regarded as
legitimate, valuable additions to the armamentarium of
professional medical care, particularly if their value can
be demonstrated repeatedly in rigorously designed trials.
First and foremost, this trial seeks to make a scientific
contribution to the field of depression and anxiety treat-
ment among PwE. This will be the first trial in which an
Internet-based intervention is evaluated that has been
designed specifically to address the unique needs of
PwE. It is also one of the few such trials in which diag-
noses are established by a structured, validated inter-
view. Several additional methodological strengths are
noteworthy, including follow-up assessments and the
inclusion of an array of validated measures for the pri-
mary outcome of depression and secondary outcomes
such as anxiety, quality of life, epilepsy disease status,
and potential negative effects of treatment, which are
highly relevant for the quality and safety management of
novel Internet interventions. As in most studies, these
strengths are balanced by some methodological limita-
tions, including the lack of clinician outcome-ratings,
laboratory tests, or brain imaging measures. Studies util-
izing such methods are desirable but costly, and it is
hoped that future investigations, including health-
economic studies, will further explore the effects and
utility of the novel, Internet-based intervention de-
scribed and tested in this trial.
Trial status
Recruitment is ongoing. It is anticipated that the trial
will be completed (T3) by October 2017.
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